<DOC>
	<DOC>NCT02927769</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab + brentuximab vedotin, followed by brentuximab vedotin + bendamustine for participants with a suboptimal response, is safe and effective in the treatment of classic Hodgkin lymphoma (cHL) in children, adolescents, and young adults after failure of first line therapy.</brief_summary>
	<brief_title>A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Classic Hodgkin Lymphoma (cHL), relapsed or refractory Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants &gt; 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age. One prior anticancer therapy that did not work Active, known, or suspected autoimmune disease or infection Active cerebral/meningeal disease related to the underlying malignancy More than one line of anticancer therapy or no treatment at all Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant Prior treatment with any drug that targets T cell costimulation pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>